193 related articles for article (PubMed ID: 35694983)
1. Biomarkers in Inflammatory Bowel Diseases: Predicting the Indication and the Effect of Biologics.
Tarapatzi G; Filidou E; Kandilogiannakis L; Vradelis S; Kolios G
J Gastrointestin Liver Dis; 2022 Jun; 31(2):229-243. PubMed ID: 35694983
[TBL] [Abstract][Full Text] [Related]
2. Biologics in Pediatric Inflammatory Bowel Disease.
Kleinhenz J; Wagner E
Pediatr Ann; 2022 Feb; 51(2):e77-e81. PubMed ID: 35156888
[TBL] [Abstract][Full Text] [Related]
3. Genetic Variants Associated with Biological Treatment Response in Inflammatory Bowel Disease: A Systematic Review.
Plaza J; Mínguez A; Bastida G; Marqués R; Nos P; Poveda JL; Moret-Tatay I
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612528
[TBL] [Abstract][Full Text] [Related]
4. Optimizing Selection of Biologics in Inflammatory Bowel Disease: Development of an Online Patient Decision Aid Using Conjoint Analysis.
Almario CV; Keller MS; Chen M; Lasch K; Ursos L; Shklovskaya J; Melmed GY; Spiegel BMR
Am J Gastroenterol; 2018 Jan; 113(1):58-71. PubMed ID: 29206816
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring in inflammatory bowel disease: At the right time in the right place.
Truta B
World J Gastroenterol; 2022 Apr; 28(13):1380-1383. PubMed ID: 35645545
[TBL] [Abstract][Full Text] [Related]
6. The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization.
Kuenzig ME; Benchimol EI; Lee L; Targownik LE; Singh H; Kaplan GG; Bernstein CN; Bitton A; Nguyen GC; Lee K; Cooke-Lauder J; Murthy SK
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S17-S33. PubMed ID: 31294382
[TBL] [Abstract][Full Text] [Related]
7. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
[TBL] [Abstract][Full Text] [Related]
8. Choosing the right biologic for complications of inflammatory bowel disease.
Rakowsky S; Papamichael K; Cheifetz AS
Expert Rev Gastroenterol Hepatol; 2022 Mar; 16(3):235-249. PubMed ID: 35094628
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of biologic versus non-biologic treatments and the health-related quality of life among a sample of patients with inflammatory bowel disease in a tertiary care center in Saudi Arabia.
AlRuthia Y; Almadi M; Aljebreen A; Azzam N; Alsharif W; Alrasheed H; Almuaythir G; Saeed M; HajkhderMullaissa B; Alharbi O
J Med Econ; 2020 Oct; 23(10):1102-1110. PubMed ID: 32619388
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory bowel disease in India - Past, present and future.
Ray G
World J Gastroenterol; 2016 Sep; 22(36):8123-36. PubMed ID: 27688654
[TBL] [Abstract][Full Text] [Related]
11. Current therapeutic approaches in inflammatory bowel disease.
Sohrabpour AA; Malekzadeh R; Keshavarzian A
Curr Pharm Des; 2010; 16(33):3668-83. PubMed ID: 21128898
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review.
Cao WT; Huang R; Jiang KF; Qiao XH; Wang JJ; Fan YH; Xu Y
World J Gastroenterol; 2021 Mar; 27(9):886-907. PubMed ID: 33727776
[TBL] [Abstract][Full Text] [Related]
13. Combining Biologics in Inflammatory Bowel Disease and Other Immune Mediated Inflammatory Disorders.
Hirten RP; Iacucci M; Shah S; Ghosh S; Colombel JF
Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1374-1384. PubMed ID: 29481970
[TBL] [Abstract][Full Text] [Related]
14. Serum matrix metalloproteinase-9 concentration as a marker of disease activity in patients with inflammatory bowel disease.
Shamseya AM; Hussein WM; Elnely DA; Adel F; Header DA
Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e803-e809. PubMed ID: 34678857
[TBL] [Abstract][Full Text] [Related]
15. Biologic therapy for inflammatory bowel disease.
Ardizzone S; Bianchi Porro G
Drugs; 2005; 65(16):2253-86. PubMed ID: 16266194
[TBL] [Abstract][Full Text] [Related]
16. The Impact of Inflammatory Bowel Disease in Canada 2018: Children and Adolescents with IBD.
Carroll MW; Kuenzig ME; Mack DR; Otley AR; Griffiths AM; Kaplan GG; Bernstein CN; Bitton A; Murthy SK; Nguyen GC; Lee K; Cooke-Lauder J; Benchimol EI
J Can Assoc Gastroenterol; 2019 Feb; 2(Suppl 1):S49-S67. PubMed ID: 31294385
[TBL] [Abstract][Full Text] [Related]
17. [Role of anti-TNF therapy (biologics) in the treatment of chronic inflammatory bowel disease in children].
Kolacek S
Acta Med Croatica; 2013 Apr; 67(2):89-92. PubMed ID: 24471292
[TBL] [Abstract][Full Text] [Related]
18. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.
Ahluwalia B; Moraes L; Magnusson MK; Öhman L
Scand J Gastroenterol; 2018 Apr; 53(4):379-389. PubMed ID: 29523023
[TBL] [Abstract][Full Text] [Related]
19. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
20. Microbiome characterization and re-design by biologic agents for inflammatory bowel disease insights.
Chen W; Chen H; Fu S; Lin X; Zheng Z; Zhang J
Bioprocess Biosyst Eng; 2021 May; 44(5):929-939. PubMed ID: 32458051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
